King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
11:09
The USA suspects Russia in the case of the explosive drone discovered at the airport in Leipzig, near a Ukrainian cargo plane. German authorities continue the investigation.
10:59
Budget revenues from gambling halls have significantly decreased following the ban on slot machines in many localities.
10:55
Reuters: Ukraine is considering transporting grain by rail, through Moldova, to Constanta.
10:53
Ukraine: At least nine new victims following the Russian attacks on Monday night
10:51
SRI has trained over 1,000 teachers to identify students at risk of radicalization. A Snoop investigation reveals a lack of transparency regarding the courses.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
